Ana Cascalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Cascalho has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Elena Coccia
Icahn School of Medicine Icahn School of Medicine Mount Sinai Mount Sinai
2 shared publications - Joel Blanchard
Nash Family Department of Neuroscience & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
2 shared publications - Peter Vangheluwe
Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
2 shared publications - Rose E. Goodchild
Vlaams Instituut voor Biotechnologie Centre for the Biology of Disease, Leuven, Belgium
2 shared publications - Rose E. Goodchild
KU Leuven Department of Neurosciences, Leuven Brain Institute , Leuven , Belgium
2 shared publications - Veerle Baekelandt
Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency
Pathogenic variants in ATP13A2 , which encodes an endolysosomal polyamine exporter, cause Kufor-Rakeb syndrome and are associated with early-onset parkinsonism and related neurodegenerative disorders; however, the mechanisms by which ATP13A2 dysfunction drives disease remain incompletely defined. In Atp13a2 knockout mice, we identified an early, transient reduction in brain polyamines that precedes overt gliosis and behavioural abnormalities. Pharmacological polyamine depletion exacerbates phenotypes, whereas oral supplementation of spermidine, but not spermine, rescues parkinsonian symptoms establishing metabolic polyamine deficiency as a pathogenic driver. Mechanistically, spermidine counteracts microglia lysosomal dysfunction in the brain and exerts mitochondrial antioxidant and anti-inflammatory effects in primary mouse microglia, thereby improving neuronal integrity. In the absence of Atp13a2, microglial spermidine import relies on the related polyamine transporter Atp13a3. Importantly, these findings translate to human systems, whereby spermidine attenuates inflammation in ATP13A2-deficient human differentiated microglia, while postmortem ATP13A2-deficient brain analysis confirms increased microglia reactivity. Spermidine also rescues motor deficits and dopaminergic neuron loss in ATP13A2-deficient Drosophila and other fly parkinsonism models. Together, these findings identify early polyamine dysregulation as a mechanistic contributor to ATP13A2-associated parkinsonism and nominate spermidine supplementation as a potential therapeutic strategy for ATP13A2-driven pathology and possibly a broader range of parkinsonian sub-types.
Open AccessSpermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency
Pathogenic variants in ATP13A2 , which encodes an endolysosomal polyamine exporter, cause Kufor-Rakeb syndrome and are associated with early-onset parkinsonism and related neurodegenerative disorders; however, the mechanisms by which ATP13A2 dysfunction drives disease remain incompletely defined. In Atp13a2 knockout mice, we identified an early, transient reduction in brain polyamines that precedes overt gliosis and behavioural abnormalities. Pharmacological polyamine depletion exacerbates phenotypes, whereas oral supplementation of spermidine, but not spermine, rescues parkinsonian symptoms establishing metabolic polyamine deficiency as a pathogenic driver. Mechanistically, spermidine counteracts microglia lysosomal dysfunction in the brain and exerts mitochondrial antioxidant and anti-inflammatory effects in primary mouse microglia, thereby improving neuronal integrity. In the absence of Atp13a2, microglial spermidine import relies on the related polyamine transporter Atp13a3. Importantly, these findings translate to human systems, whereby spermidine attenuates inflammation in ATP13A2-deficient human differentiated microglia, while postmortem ATP13A2-deficient brain analysis confirms increased microglia reactivity. Spermidine also rescues motor deficits and dopaminergic neuron loss in ATP13A2-deficient Drosophila and other fly parkinsonism models. Together, these findings identify early polyamine dysregulation as a mechanistic contributor to ATP13A2-associated parkinsonism and nominate spermidine supplementation as a potential therapeutic strategy for ATP13A2-driven pathology and possibly a broader range of parkinsonian sub-types.
- Open Access
Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits
Background: ATP10B, a transmembrane lipid flippase located in late endosomes and lysosomes, facilitates the export of glucosylceramide and phosphatidylcholine by coupling this process to ATP hydrolysis. Recently, loss-of-function mutations in the ATP10B gene have been identified in Parkinson’s disease patients, pointing to ATP10B as a candidate genetic risk factor. Previous studies have shown compromised lysosomal functionality upon ATP10B knockdown in human cell lines and primary cortical neurons. However, its role in vivo and specifically in the nigrostriatal dopaminergic system remains poorly understood. Methods: To investigate the role ATP10B in PD neuropathology, we induced ATP10B knockdown specifically in substantia nigra pars compacta neurons of rats using viral vector technology. Two different microRNA-based shRNA constructs targeting distinct regions of the ATP10B mRNA were used to cross-validate the findings. Behavioral evaluation, dopamine transporter 18 F-FE-PE2I positron emission tomography imaging and neuropathological examination of the nigrostriatal pathway at one year post-injection were conducted. Additionally, midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones were used to study the impact of ATP10B loss in dopaminergic neurons in a more translational model. Results: ATP10B knockdown in rat brain induced Parkinsonian motor deficits, and longitudinal striatal dopamine transporter 18 F-FE-PE2I PET imaging revealed a progressive decrease in binding potential. Immunohistochemical analysis conducted one year post-injection confirmed the loss of dopaminergic terminals in the striatum , alongside a loss of dopaminergic neurons in the substantia nigra pars compacta . The expression of LAMP1, LAMP2a, cathepsin B and glucocerebrosidase was studied by immunofluorescence in the surviving dopaminergic neurons. A decrease in lysosomal numbers and an increase in lysosomal volume were observed more consistently in one of the knockdown constructs. The vulnerability of dopaminergic neurons to ATP10B loss-of-function was also observed in midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones, which showed a significant reduction in TH-positive neurons. Conclusion: Taken together, our findings demonstrate that ATP10B depletion detrimentally impacts the viability of dopaminergic neurons both in vivo and in vitro . Moreover, a broader impact on the functionality of the nigrostriatal pathway was evidenced as rats with ATP10B knockdown exhibited motor impairments similar to those observed in PD patients.
Open AccessLoss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits
Background: ATP10B, a transmembrane lipid flippase located in late endosomes and lysosomes, facilitates the export of glucosylceramide and phosphatidylcholine by coupling this process to ATP hydrolysis. Recently, loss-of-function mutations in the ATP10B gene have been identified in Parkinson’s disease patients, pointing to ATP10B as a candidate genetic risk factor. Previous studies have shown compromised lysosomal functionality upon ATP10B knockdown in human cell lines and primary cortical neurons. However, its role in vivo and specifically in the nigrostriatal dopaminergic system remains poorly understood. Methods: To investigate the role ATP10B in PD neuropathology, we induced ATP10B knockdown specifically in substantia nigra pars compacta neurons of rats using viral vector technology. Two different microRNA-based shRNA constructs targeting distinct regions of the ATP10B mRNA were used to cross-validate the findings. Behavioral evaluation, dopamine transporter 18 F-FE-PE2I positron emission tomography imaging and neuropathological examination of the nigrostriatal pathway at one year post-injection were conducted. Additionally, midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones were used to study the impact of ATP10B loss in dopaminergic neurons in a more translational model. Results: ATP10B knockdown in rat brain induced Parkinsonian motor deficits, and longitudinal striatal dopamine transporter 18 F-FE-PE2I PET imaging revealed a progressive decrease in binding potential. Immunohistochemical analysis conducted one year post-injection confirmed the loss of dopaminergic terminals in the striatum , alongside a loss of dopaminergic neurons in the substantia nigra pars compacta . The expression of LAMP1, LAMP2a, cathepsin B and glucocerebrosidase was studied by immunofluorescence in the surviving dopaminergic neurons. A decrease in lysosomal numbers and an increase in lysosomal volume were observed more consistently in one of the knockdown constructs. The vulnerability of dopaminergic neurons to ATP10B loss-of-function was also observed in midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones, which showed a significant reduction in TH-positive neurons. Conclusion: Taken together, our findings demonstrate that ATP10B depletion detrimentally impacts the viability of dopaminergic neurons both in vivo and in vitro . Moreover, a broader impact on the functionality of the nigrostriatal pathway was evidenced as rats with ATP10B knockdown exhibited motor impairments similar to those observed in PD patients.
- Open Access
- 28 September 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2234
Mice Deficient in Nucleoporin Nup210 Develop Peripheral T Cell Alterations
The nucleopore is an essential structure of the eukaryotic cell, regulating passage between the nucleus and cytoplasm. While individual functions of core nucleopore proteins have been identified, the role of other components, such as Nup210, are poorly defined. Here, through the use of an unbiased ENU mutagenesis screen for mutations effecting the peripheral T cell compartment, we identified a Nup210 mutation in a mouse strain with altered CD4/CD8 T cell ratios. Through the generation of Nup210 knockout mice we identified Nup210 as having a T cell-intrinsic function in the peripheral homeostasis of T cells. Remarkably, despite the deep evolutionary conservation of this key nucleopore complex member, no other major phenotypes developed, with viable and healthy knockout mice. These results identify Nup210 as an important nucleopore complex component for peripheral T cells, and raise further questions of why this nucleopore component shows deep evolutionary conservation despite seemingly redundant functions in most cell types.
- 28 September 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2234
Open AccessMice Deficient in Nucleoporin Nup210 Develop Peripheral T Cell Alterations
The nucleopore is an essential structure of the eukaryotic cell, regulating passage between the nucleus and cytoplasm. While individual functions of core nucleopore proteins have been identified, the role of other components, such as Nup210, are poorly defined. Here, through the use of an unbiased ENU mutagenesis screen for mutations effecting the peripheral T cell compartment, we identified a Nup210 mutation in a mouse strain with altered CD4/CD8 T cell ratios. Through the generation of Nup210 knockout mice we identified Nup210 as having a T cell-intrinsic function in the peripheral homeostasis of T cells. Remarkably, despite the deep evolutionary conservation of this key nucleopore complex member, no other major phenotypes developed, with viable and healthy knockout mice. These results identify Nup210 as an important nucleopore complex component for peripheral T cells, and raise further questions of why this nucleopore component shows deep evolutionary conservation despite seemingly redundant functions in most cell types.
- 21 December 2017
- Published by Wiley in Movement Disorders
- Vol. 33 (1) , 73
New twist defines a spectrum of TOR1A neurological disease
- 21 December 2017
- Published by Wiley in Movement Disorders
- Vol. 33 (1) , 73
New twist defines a spectrum of TOR1A neurological disease
- Top Cited Papers
- 26 October 2017
- Published by Springer Nature in EMBO Reports
- Vol. 18 (11) , 1905-1921
The ins and outs of endoplasmic reticulum‐controlled lipid biosynthesis
Endoplasmic reticulum (ER)‐localized enzymes synthesize the vast majority of cellular lipids. The ER therefore has a major influence on cellular lipid biomass and balances the production of different lipid categories, classes, and species. Signals from outside and inside the cell are directed to ER‐localized enzymes, and lipid enzyme activities are defined by the integration of internal, homeostatic, and external information. This allows ER‐localized lipid synthesis to provide the cell with membrane lipids for growth, proliferation, and differentiation‐based changes in morphology and structure, and to maintain membrane homeostasis across the cell. ER enzymes also respond to physiological signals to drive carbohydrates and nutritionally derived lipids into energy‐storing triglycerides. In this review, we highlight some key regulatory mechanisms that control ER‐localized enzyme activities in animal cells. We also discuss how they act in concert to maintain cellular lipid homeostasis, as well as how their dysregulation contributes to human disease.
- 26 October 2017
- Published by Springer Nature in EMBO Reports
- Vol. 18 (11) , 1905-1921
Top Cited PapersThe ins and outs of endoplasmic reticulum‐controlled lipid biosynthesis
Endoplasmic reticulum (ER)‐localized enzymes synthesize the vast majority of cellular lipids. The ER therefore has a major influence on cellular lipid biomass and balances the production of different lipid categories, classes, and species. Signals from outside and inside the cell are directed to ER‐localized enzymes, and lipid enzyme activities are defined by the integration of internal, homeostatic, and external information. This allows ER‐localized lipid synthesis to provide the cell with membrane lipids for growth, proliferation, and differentiation‐based changes in morphology and structure, and to maintain membrane homeostasis across the cell. ER enzymes also respond to physiological signals to drive carbohydrates and nutritionally derived lipids into energy‐storing triglycerides. In this review, we highlight some key regulatory mechanisms that control ER‐localized enzyme activities in animal cells. We also discuss how they act in concert to maintain cellular lipid homeostasis, as well as how their dysregulation contributes to human disease.
- 2 December 2016
- Published by Wiley in Movement Disorders
- Vol. 32 (3) , 371-381
Membrane defects and genetic redundancy: Are we at a turning point for DYT1 dystonia?
Heterozygosity for a 3‐base pair deletion (ΔGAG) in TOR1A/torsinA is one of the most common causes of hereditary dystonia. In this review, we highlight current understanding of how this mutation causes disease from research spanning structural biochemistry, cell science, neurobiology, and several model organisms. We now know that homozygosity for ΔGAG has the same effects as Tor1aKO, implicating a partial loss of function mechanism in the ΔGAG/+ disease state. In addition, torsinA loss specifically affects neurons in mice, even though the gene is broadly expressed, apparently because of differential expression of homologous torsinB. Furthermore, certain neuronal subtypes are more severely affected by torsinA loss. Interestingly, these include striatal cholinergic interneurons that display abnormal responses to dopamine in several Tor1a animal models. There is also progress on understanding torsinA molecular cell biology. The structural basis of how ΔGAG inhibits torsinA ATPase activity is defined, although mutant torsinAΔGAG protein also displays some characteristics suggesting it contributes to dystonia by a gain‐of‐function mechanism. Furthermore, a consistent relationship is emerging between torsin dysfunction and membrane biology, including an evolutionarily conserved regulation of lipid metabolism. Considered together, these findings provide major advances toward understanding the molecular, cellular, and neurobiological pathologies of DYT1/TOR1A dystonia that can hopefully be exploited for new approaches to treat this disease. © 2016 International Parkinson and Movement Disorder Society
- 2 December 2016
- Published by Wiley in Movement Disorders
- Vol. 32 (3) , 371-381
Membrane defects and genetic redundancy: Are we at a turning point for DYT1 dystonia?
Heterozygosity for a 3‐base pair deletion (ΔGAG) in TOR1A/torsinA is one of the most common causes of hereditary dystonia. In this review, we highlight current understanding of how this mutation causes disease from research spanning structural biochemistry, cell science, neurobiology, and several model organisms. We now know that homozygosity for ΔGAG has the same effects as Tor1aKO, implicating a partial loss of function mechanism in the ΔGAG/+ disease state. In addition, torsinA loss specifically affects neurons in mice, even though the gene is broadly expressed, apparently because of differential expression of homologous torsinB. Furthermore, certain neuronal subtypes are more severely affected by torsinA loss. Interestingly, these include striatal cholinergic interneurons that display abnormal responses to dopamine in several Tor1a animal models. There is also progress on understanding torsinA molecular cell biology. The structural basis of how ΔGAG inhibits torsinA ATPase activity is defined, although mutant torsinAΔGAG protein also displays some characteristics suggesting it contributes to dystonia by a gain‐of‐function mechanism. Furthermore, a consistent relationship is emerging between torsin dysfunction and membrane biology, including an evolutionarily conserved regulation of lipid metabolism. Considered together, these findings provide major advances toward understanding the molecular, cellular, and neurobiological pathologies of DYT1/TOR1A dystonia that can hopefully be exploited for new approaches to treat this disease. © 2016 International Parkinson and Movement Disorder Society
- 1 August 2016
- Published by Elsevier in Developmental Cell
- Vol. 38 (3) , 235-247
Torsins Are Essential Regulators of Cellular Lipid Metabolism
- 1 August 2016
- Published by Elsevier in Developmental Cell
- Vol. 38 (3) , 235-247
Torsins Are Essential Regulators of Cellular Lipid Metabolism
- 1 July 2016
- Published by Wiley in Alzheimer's & Dementia
- Vol. 12 (7S_Part_13)
P2‐045: Effect of Bace Inhibitor Treatment on Full‐Length and N‐Truncated AB Species in Cellular and Canine Models
- 1 July 2016
- Published by Wiley in Alzheimer's & Dementia
- Vol. 12 (7S_Part_13)
P2‐045: Effect of Bace Inhibitor Treatment on Full‐Length and N‐Truncated AB Species in Cellular and Canine Models